BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

Completed

Conditions: Venous Thromboembolism

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)

First Posted Date: 2017-07-11

Last Posted Date: 2018-09-06

Lead Sponsor: Bayer

Target Recruit Count: 1000

Registration Number: NCT03214172

Locations: 🇺🇸
US database, New York, New York, United States

Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)

Phase 1

Completed

Conditions: Clinical Trial ,Phase I

Interventions: Drug: Vilaprisan (BAY 1002670)
Drug: Vilaprisan Placebo
Drug: Microgynon
Drug: Microgynon Placebo

First Posted Date: 2017-07-06

Last Posted Date: 2019-02-28

Lead Sponsor: Bayer

Target Recruit Count: 71

Registration Number: NCT03210246

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
🇩🇪
Dinox GmbH Berlin, Berlin, Germany

Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Conditions: Solid Tumors Harboring NTRK Fusion

First Posted Date: 2017-07-02

Last Posted Date: 2021-09-16

Lead Sponsor: Bayer

Registration Number: NCT03206931

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

Phase 3

Terminated

Conditions: Uterine Fibroids

Interventions: Other: Standard of care
Drug: Vilaprisan (BAY1002670)

First Posted Date: 2017-06-21

Last Posted Date: 2024-08-27

Lead Sponsor: Bayer

Target Recruit Count: 1272

Registration Number: NCT03194646

Locations: 🇺🇸
Baltimore Suburban Health, LLC, Pikesville, Maryland, United States
🇺🇸
Advances in Health, INC. | Houston, TX, Houston, Texas, United States
🇺🇸
Coastal Clinical Research, Inc, Mobile, Alabama, United States

and more 216 locations

Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study

Completed

Conditions: Hypertension

Interventions: Drug: Nifedipine controlled-release tablets(Nifedipine GITS, ADALAT, BAYA1040)

First Posted Date: 2017-06-21

Last Posted Date: 2021-07-09

Lead Sponsor: Bayer

Target Recruit Count: 871

Registration Number: NCT03194633

Locations: 🇨🇳
Many Locations, Multiple Locations, China

First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

Phase 1

Completed

Conditions: Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma
Advanced Solid Tumor

Interventions: Drug: Elimusertib (BAY1895344)

First Posted Date: 2017-06-16

Last Posted Date: 2023-10-11

Lead Sponsor: Bayer

Target Recruit Count: 229

Registration Number: NCT03188965

Locations: 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸
Fairfax-Northern Virginia Hematology/Oncology, PC, Fairfax, Virginia, United States
🇺🇸
Emory University, Atlanta, Georgia, United States

and more 26 locations

KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method

Completed

Conditions: Contraception

Interventions: Drug: Kyleena

First Posted Date: 2017-06-09

Last Posted Date: 2021-03-29

Lead Sponsor: Bayer

Target Recruit Count: 1134

Registration Number: NCT03182140

Locations: 🇺🇸
Visions Clinical Research, Wellington, Florida, United States
🇺🇸
Saginaw Valley Medical Research Group, LLC, Saginaw, Michigan, United States
🇸🇪
Many locations, Multiple Locations, Sweden

and more 10 locations

Study of Copanlisib in Hepatic or Renal Impairment

Phase 1

Completed

Conditions: Hepatic Insufficiency, Renal Insufficiency

Interventions: Drug: Copanlisib (ALIQOPA, BAY80-6946)

First Posted Date: 2017-06-01

Last Posted Date: 2021-04-28

Lead Sponsor: Bayer

Target Recruit Count: 30

Registration Number: NCT03172884

Locations: 🇷🇴
Institutul National de Boli Infectioase Prof.Dr.Matei Bals, Bucuresti, Romania
🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany

A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease

Completed

Conditions: Macular Edema

Interventions: Drug: Aflibercept (Eylea, BAY86-5321)

First Posted Date: 2017-05-22

Last Posted Date: 2022-11-14

Lead Sponsor: Bayer

Target Recruit Count: 2481

Registration Number: NCT03161912

Locations: 🇦🇪
Many Locations, Multiple Locations, United Arab Emirates

Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects

Phase 1

Completed

Conditions: Pharmacokinetics

Interventions: Drug: Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed
Drug: Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast
Drug: Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast
Drug: Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed
Drug: Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted
Drug: Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast

First Posted Date: 2017-05-09

Last Posted Date: 2021-12-29

Lead Sponsor: Bayer

Target Recruit Count: 30

Registration Number: NCT03145038

Locations: 🇩🇪
CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy